Conjunctival melanoma: A review of conceptual and treatment advances

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 521-531

  Lim, Li Anne ^a   Madigan, Michele C ^a,b   Max Conway, R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adjuvant therapy; Melanoma in situ; Metastases; Mitomycin C

Indexed keywords

MITOMYCIN; RECOMBINANT ALPHA2B INTERFERON;

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CONJUNCTIVA MELANOMA; CONJUNCTIVA TUMOR; CONJUNCTIVAL MELANOMA; CRYOTHERAPY; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; MELANOMA; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RECURRENCE RISK; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

EID: 84875177933     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S38415     Document Type: Review

References (74)

1. Seregard S. Conjunctival melanoma. Surv Ophthalmol. 1998;42(4): 321-350.
2. Isager P, Engholm G, Overgaard J, Storm H. Uveal and conjunctival malignant melanoma in Denmark 1943-1997: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol. 2006; 13(2):85-96.
3. Vajdic CM, Kricker A, Giblin M, et al. Incidence of ocular melanoma in Australia from 1990 to 1998. Int J Cancer. 2003;105(1):117-122.
4. Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. 2009;93(11):1524-1528.
5. Tuomaala S, Eskelin S, Tarkkanen A, Kivelä T. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci. 2002;43(11): 3399-3408.
6. Yu G P, Hu DN, McCormick S, Finger PT. Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol. 2003;135(6): 800-806.
7. Inskip PD, Devesa SS, Fraumeni JF. Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control. 2003;14(3):251-257.
8. Greene FL, Page DL, Fleming ID, et al, editors. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.
9. Paridaens AD, McCartney AC, Minassian DC, Hungerford JL. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol. 1994;78(7):520-528.
10. Paridaens AD, Minassian DC, McCartney AC, Hungerford JL. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol. 1994;78(4): 252-259.
11. Lommatzsch PK, Lommatzsch RE, Kirsch I, Fuhrmann P. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol. 1990;74(10):615-619.
12. Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radio-therapy in a Danish population. Graefes Arch Clin Exp Ophthalmol. 1996;234(9):569-572.
13. Seregard S, Kock E. Conjunctival malignant melanoma in Sweden 1969-1991. Acta Ophthalmol (Copenh). 1992;70(3):289-296.
14. Werschnik C, Lommatzsch PK. Long-term follow-up of patients with conjunctival melanoma. Am J Clin Oncol. 2002;25(3):248-255.
15. Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001; 108(11):2101-2105.
16. Tuomaala S, KivelIä T. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmolog y. 2004;111(4):816-821.
17. Tuomaala S, Toivonen P, Al-Jamal R, Kivelä T. Prognostic significance of histopathology of primary conjunctival melanoma in Caucasians. Curr Eye Res. 2007;32(11):939-952.
18. Missotten GS, Keijser S, De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci. 2005;46(1):75-82.
19. Isager P, Østerlind A, Engholm G, et al. Uveal and conjunctival malignant melanoma in Denmark, 1943-1997: incidence and validation study. Ophthalmic Epidemiol. 2005;12(4):223-232.
20. Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl K P. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol. 2002;86(2):163-167.
21. Bobić-Radovanović A, Latković Z, Marinković J, Radovanović Z. Predictors of survival in malignant melanoma of the conjunctiva: a clinico-pathological and follow-up study. Eur J Ophthalmol. 1998;8(1):4-7.
22. Damato B, Coupland SE. An audit of conjunctival melanoma treatment in Liverpool. Eye (Lond). 2009;23(4):801-809.
23. De Potter P, Shields CL, Shields JA, Menduke H. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol. 1993;77(10):624-630.
24. Shields CL, Shields JA, Gündüz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol. 2000;118(11):1497-1507.
25. Folberg R, McLean I W, Zimmerman LE. Malignant melanoma of the conjunctiva. Hum Pathol. 1985;16(2):136-143.
26. Karim R, Conway RM. Conservative resection and adjuvant plaque brachytherapy for early-stage conjunctival melanoma. Clin Experiment Ophthalmol. 2011;39(4):293-298.
27. Walsh-Conway N, Conway RM. Plaque brachytherapy for the management of ocular surface malignancies with corneoscleral invasion. Clin Experiment Ophthalmol. 2009;37(6):577-583.
28. Crawford JB. Conjunctival melanomas: prognostic factors; a review and an analysis of a series. Trans Am Ophthalmol Soc. 1980;78:467-502.
29. Anastassiou G, Esser M, Bader E, Steuhl K P, Bornfeld N. Expression of cell adhesion molecules and tumour infiltrating leucocytes in conjunctival melanoma. Melanoma Res. 2004;14(5):381-385.
30. Coleman K, Norris S, Weston A, et al; National Health and Medical Research Council. NHMRC Additional Levels of Evidence and Grades for Recommendations for Developers of Guidelines: Stage 2 Consultation; Early 2008 - End Jun 2009. Canberra, Australia: National Health and Medical Research Council; 2009. Available from: http://www.nhmrc.gov.au/_fles_nhmrc/fle/guidelines/stage_2_consultation_lev-els_and_grades.pdf. Accessed August 19, 2010.
31. Folberg R, McLean I W, Zimmerman LE. Primary acquired melanosis of the conjunctiva. Hum Pathol. 1985;16(2):129-135.
32. Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmolog y. 1989;96(2):147-166.
33. Damato B, Coupland SE. Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Experiment Ophthalmol. 2008;36(8):786-795.
34. Edge SB, Byrd DR, Compton CC, editors. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
35. Harooni H, Schoenfeld LR, Singh AD. Current appraisal of conjunctival melanocytic tumors: classification and treatment. Future Oncol. 2011;7(3):435-446.
36. Steuhl K P, Rohrbach JM, Knorr M, Thiel HJ. Significance, specifcity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology. 1993;100(2):208-215.
37. Heegaard S, Jensen OA, Prause JU. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res. 2000;10(4):350-354.
38. Keijser S, Missotten GS, Bonfrer JM, de Wolff-Rouendaal D, Jager MJ, de Keizer RJ. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions. Br J Ophthalmol. 2006; 90(2):213-217.
39. Sharara NA, Alexander RA, Luthert PJ, Hungerford JL, Cree IA. Differential immunoreactivity of melanocytic lesions of the conjunctiva. Histopathology. 2001;39(4):426-431.
40. Jakobiec FA, Bhat P, Colby KA. Immunohistochemical studies of conjunctival nevi and melanomas. Arch Ophthalmol. 2010;128(2): 174-183.
41. McDonnell JM, Sun YY, Wagner D. HMB-45 immunohistochemical staining of conjunctival melanocytic lesions. Ophthalmology. 1991; 98(4):453-458.
42. Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases. Arch Ophthalmol. 2009; 127(8):964-969.
43. Maly A, Epstein D, Meir K, Pe'er J. Histological criteria for grading of atypia in melanocytic conjunctival lesions. Pathology. 2008;40(7):676-681.
44. Lake SL, Jmor F, Dopierala J, Taktak A F, Coupland SE, Damato BE. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci. 2011;52(8):5598-5604.
45. Gear H, Williams H, Kemp EG, Roberts F. BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci. 2004;45(8):2484-2488.
46. Spendlove HE, Damato BE, Humphreys J, Barker KT, Hiscott PS, Houlston RS. BRAF mutations are detectable in conjunctival but not uveal melanomas. Melanoma Res. 2004;14(6):449-452.
47. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14(21): 6821-6828.
48. Shields JA, Shields CL, Mashayekhi A, et al. Primary acquired melanosis of the conjunctiva: risks for progression to melanoma in 311 eyes. The 2006 Lorenz E. Zimmerman lecture. Ophthalmology. 2008;115(3): 511-519.e2.
49. Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389-395.e2.
50. Heindl LM, Hofmann-Rummelt C, Adler W, et al. Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci. 2011;52(10):7074-7083.
51. Heindl LM, Hofmann-Rummelt C, Adler W, et al. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology. 2011;118(12):2351-2360.
52. Ho VH, Prager TC, Diwan H, Prieto V, Esmaeli B. Ultrasound biomicroscopy for estimation of tumor thickness for conjunctival melanoma. J Clin Ultrasound. 2007;35(9):533-537.
53. Tuomaala S, Kivelä T. Sentinel lymph node biopsy guidelines for conjunctival melanoma. Melanoma Res. 2008;18(3):235.
54. Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol. 1997;115(6):808-815.
55. Damato B, Coupland SE. Management of conjunctival melanoma. Expert Rev Anticancer Ther. 2009;9(9):1227-1239.
56. Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas. Ophthal Plast Reconstr Surg. 1998; 14(3):208-215.
57. Tucker SM, Hurwitz JJ, Pavlin CJ, Howarth DJ, Nianiaris N. Scleral melt after cryotherapy for conjunctival melanoma. Ophthalmology. 1993;100(4):574-577.
58. Jakobiec FA, Rini FJ, Fraunfelder FT, Brownstein S. Cryotherapy for conjunctival primary acquired melanosis and malignant melanoma: experience with 62 cases. Ophthalmology. 1988;95(8):1058-1070.
59. Chalasani R, Giblin M, Conway RM. Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment. Clin Experiment Ophthalmol. 2006;34(7):708-714.
60. Wilson MW, Czechonska G, Finger PT, Rausen A, Hooper ME, Haik BG. Chemotherapy for eye cancer. Surv Ophthalmol. 2001;45(5): 416-444.
61. Kurli M, Finger PT. Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol. 2005;243(11): 1108-1114.
62. Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol. 1998;82(5):476-479.
63. Ditta LC, Shildkrot Y, Wilson M W. Outcomes in 15 patients with conjunctival melanoma treated with adjuvant topical mitomycin C: complications and recurrences. Ophthalmology. 2011;118(9):1754-1759.
64. Stannard CE, Sealy GR, Hering ER, Pereira SB, Knowles R, Hill JC. Malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology. 2000;107(5): 951-958.
65. Wuestemeyer H, Sauerwein W, Meller D, et al. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol. 2006;244(4): 438-446.
66. Codère F, Brownstein S, Garwood JL, Dresner SC. Carbon dioxide laser treatment of the conjunctiva and the cornea. Ophthalmology. 1988;95(1):37-45.
67. Finger PT, Sedeek RW, Chin KJ. Topical interferon alfa in the treatment of conjunctival melanoma and primary acquired melanosis complex. Am J Ophthalmol. 2008;145(1):124-129.
68. Herold TR, Hintschich C. Interferon alpha for the treatment of melanocytic conjunctival lesions. Graefes Arch Clin Exp Ophthalmol. 2010; 248(1):111-115.
69. Esmaeli B. Advances in the management of malignant tumors of the eyelid and conjunctiva: the role of sentinel lymph node biopsy. Int Ophthalmol Clin. 2002;42(2):151-162.
70. Esmaeli B. Regional lymph node assessment for conjunctival melanoma: sentinel lymph node biopsy and positron emission tomography. Br J Ophthalmol. 2008;92(4):443-445.
71. Brownstein S. Malignant melanoma of the conjunctiva. Cancer Control. 2004;11(5):310-316.
72. Baroody M, Holds JB, Kokoska MS, Boyd J. Conjunctival melanoma metastasis diagnosed by sentinel lymph node biopsy. Am J Ophthalmol. 2004;137(6):1147-1149.
73. Esmaeli B, Reifer D, Prieto VG, et al. Conjunctival melanoma with a positive sentinel lymph node. Arch Ophthalmol. 2003;121(12): 1779-1783.
74. Savar A, Ross MI, Prieto VG, Ivan D, Kim S, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients. Ophthalmolog y. 2009;116(11):2217-2223.